• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Nancy Chemluo, A Mother’s Struggle to Cure a Child with Kala Azar

Nancy Cheluo had two sons affected by Kala Azar. East Pokot, Kenya.

Home > Stories

Nancy Chemluo, A Mother’s Struggle to Cure a Child with Kala Azar

Nancy Cheluo had two sons affected by Kala Azar. East Pokot, Kenya.

Nancy Cheluo had two sons affected by Kala Azar. East Pokot, Kenya.
8 May 2013

West Pokot Kenya

Thursday, 23 August 2012, a sunny and very hot afternoon in West Pokot, Kenya: Dust devils circle into the air as pickup trucks packed with passengers drop off numbers of people, who all settle under a large tree in the village. This is where the community gathers for elders’ meetings. It is here that Nancy Chemluo recounts how kala azar affected two of her sons, and how she and her community changed their approach to seeking treatment.

‘A year ago, my five-year-old son was unwell. He had fever, headache, and nose bleeds. After some investigation, we found out his symptoms were those of kala azar. We tried to treat him using home remedies, which my community is accustomed to using when someone falls ill. So if one of my neighbours or anyone I know was going to Kerio valley, I would give them the money to buy me the traditional medicine. I spent a lot of money on transport and these traditional remedies.

So many people have suffered and still suffer from kala azar in my community. We have so many anthills here, and that is where the insect that spreads kala azar lives. My message to my community and anyone who will hear me is this: traditional forms of medicine for kala azar do not work! My son took them and showed no signs of improvement. He only got worse. It was like a death sentence.
I was so desperate for a solution for him. I then had a chance meeting with one of my neighbours, who told me I could get treatment in Kimalel and gave me the mobile number of a staff member. That phone call saved my son’s life.

Since then, we as a community have come to know KEMRI and DNDi. So when my four-year-old son, Jamesta Limareng, got sick last month, my family gathered at my house and made arrangements to have him taken right away to the treatment centre in Kimalel. His recovery was much faster than that of my older son: instead of a 30-day treatment, Jamesta was treated using the 17-day treatment [SSG&PM]. The shorter and better the treatment, the better for us all.’

Visceral leishmaniasis Kenya

Read, watch, share

Loading...
Jessica Robbins
Stories
24 Oct 2025

Jessica Robbins: A long and difficult journey with cutaneous leishmaniasis

Videos
24 Oct 2025

Road to Elimination of Kala-azar in South Asia

Videos
22 Oct 2025

The Boy Who Beat the Sandfly

Viewpoints
9 Oct 2025

Pharma’s shift away from infectious disease research could spell disaster for the world’s poorest people

STAT
News
3 Oct 2025

DNDi 2025 Projects of the Year recognize contributions of DNDi teams and partners working to deliver urgently needed innovations for people affected by Chagas disease and river blindness

Nature Africa logo
Viewpoints
30 Sep 2025

Drug development for neglected diseases must account for kids

Nature Africa
Press releases
23 Sep 2025

Open-science approach delivers a promising pre-clinical candidate for broad-spectrum coronavirus antiviral 

Publications
2 Sep 2025

DNDi Brochure

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license